USPTO serial 75052402
Reviewed by CopyMark Law Group
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Martin H. Michael
MARTIN H MICHAEL AVON PRODUCTS, INC1251 AVE SE OF THE AMERICASNEW YORK, NY 10019UNITED STATES| Class | Description | Status | First use |
|---|---|---|---|
| 041 | educational services, namely creating and conducting seminars and classes in the fields of physical fitness and sports participation | ABANDONED | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 26, 1997 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| May 30, 1997 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| May 6, 1997 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 4, 1997 | NPUB | NOTICE OF PUBLICATION | — |
| Mar 13, 1997 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 23, 1997 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 8, 1996 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 7, 1996 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 30, 1996 | DOCK | ASSIGNED TO EXAMINER | — |